Evidence map›Paper›PMID 41243190›Full record

ArticleInfluenza and other respiratory viruses2025

Relative Effectiveness of High-Dose vs. Standard-Dose Influenza Vaccines in Preventing Hospitalizations: A National Retrospective Cohort Study in France, 2022/2023 Season.

Hélène Bricout, Marie-Cécile Levant, Pascal Crépey, Gaëtan Gavazzi, Jacques Gaillat, Marine Dufournet, Nada Assi, Benjamin Grenier, Fanny Raguideau, Fabienne Péretz and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hélène BricoutMedical Department, Sanofi Vaccines, Lyon, France.ORCID https://orcid.org/0000-0002-5439-8064
Marie-Cécile LevantMedical Department, Sanofi Vaccines, Lyon, France.
Pascal CrépeyEcole des Hautes Études en Santé Publique, CNRS, Université de Rennes, ARENES, UMR 6051, Recherche sur les Services et le Management en Santé, Inserm U 1309, Rennes, France.ORCID https://orcid.org/0000-0003-1852-0752
Gaëtan GavazziCHU Grenoble Alpes, Service Universitaire de Gériatrie Clinique, CS 10217, Grenoble, France.
Jacques GaillatService de Maladies Infectieuses, Centre Hospitalier Annecy Genevois, Annecy, France.
Marine DufournetBiostatistics Department, Sanofi Vaccines, Lyon, France.
Nada AssiHEVA, Pôle Statistiques, Lyon, France.
Benjamin GrenierHEVA, Pôle Epidémiologie, Lyon, France.ORCID https://orcid.org/0000-0002-2373-1872
Fanny RaguideauHEVA, Pôle Epidémiologie, Lyon, France.
Fabienne PéretzAbelia Science, Saint-Georges-sur-Baulche, France.
Camille SalamandBiostatistics Department, Sanofi Vaccines, Lyon, France.
Anne MosnierOpen Rome, Paris, France.
Laurence WatierEpidemiology and Modeling of Bacterial Escape to Antimicrobials, Institut Pasteur, Paris, France.ORCID https://orcid.org/0000-0002-4057-1102
Odile LaunayInserm CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Université Paris Cité, Paris, France.
Matthew M LoiaconoMedical Evidence Generation, Sanofi Vaccines, Swiftwater, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-8100-465X

Funding

Sanofi
6 · The paper itself

Abstract

backgroundA French cohort study (2021/2022 influenza season) found the high-dose influenza vaccine (HD) more effective than standard-dose vaccines (SDs) in preventing influenza-related hospitalizations in the elderly. The study continued to refine results and validate these findings.

methodsData from community-dwelling 65+ adults who received HD or SD during the 2022/2023 vaccination campaign were extracted from the National Health database. Hospitalizations were recorded from 14 days postvaccination until June 30, 2023. HD and SD recipients were matched using a propensity score. Associations between vaccines and hospitalizations were assessed by estimating incidence rate ratios and converting them to HD vs. SD vaccine relative effectiveness (rVE).

resultsA total of 675,412 HD recipients were matched to 2,701,648 SD recipients. The rVE for influenza-related hospitalizations was 27.4% [95% CI: 19.8; 34.3]. It ranged from 22.7% [9.8; 33.6] to 33.6% [21.2; 44.0] across age groups, indicating that HD consistently outperformed SDs in preventing influenza-related hospitalizations, with the highest effect observed in 85+.

conclusionsOur study is the first to publish rVE data comparing HD and SDs in a real-world setting in France for the 2022/2023 influenza season. Its findings reaffirm the benefit of HD vs. SDs. HD could help reduce the burden of severe respiratory infections in the elderly.

Indexed as

HospitalizationInfluenza, HumanInfluenza VaccinesVaccine EfficacyAgedAged, 80 and overFemaleFranceHumansMaleRetrospective StudiesSeasonsVaccinationInfluenza Vaccinesagedfactual databasesFrancehospitalizationinfluenza vaccinesmedical informaticsvaccine effectiveness

Identifiers

PMID41243190
PMCPMC12620122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.